Pathogenesis and outcome of biliary atresia: current concepts

RJ Sokol, C Mack, MR Narkewicz… - Journal of pediatric …, 2003 - journals.lww.com
RJ Sokol, C Mack, MR Narkewicz, FM Karrer
Journal of pediatric gastroenterology and nutrition, 2003journals.lww.com
Neonatal cholestatic disorders are a group of hepatobiliary diseases occurring within the
first 3 months of life. Bile flow is impaired, and patients have conjugated hyperbilirubinemia,
acholic stools, and hepatomegaly. Overall, 1 in 2,500 live births is affected with a neonatal
cholestatic disorder (1). The two most common causes of neonatal cholestasis are biliary
atresia and idiopathic neonatal hepatitis, accounting for up to 50% to 70% of cases. Other
causes include a variety of neonatal infections (viral, toxoplasmosis, syphilis, bacterial) …
Neonatal cholestatic disorders are a group of hepatobiliary diseases occurring within the first 3 months of life. Bile flow is impaired, and patients have conjugated hyperbilirubinemia, acholic stools, and hepatomegaly. Overall, 1 in 2,500 live births is affected with a neonatal cholestatic disorder (1). The two most common causes of neonatal cholestasis are biliary atresia and idiopathic neonatal hepatitis, accounting for up to 50% to 70% of cases. Other causes include a variety of neonatal infections (viral, toxoplasmosis, syphilis, bacterial), metabolic and genetic diseases, progressive familial intrahepatic cholestatic disorders (PFIC), paucity of interlobular bile duct disorders (eg, Alagille syndrome), choledochal cyst, ischemia–reperfusion injury, association with parenteral nutrition administration, and other conditions (Table 1). Despite clinical improvement after the portoenterostomy procedure, approximately 70% to 80% of children with biliary atresia will eventually require liver transplantation; thus, biliary atresia alone accounts for almost 50% of all liver transplants performed in children (1). It should be noted that $77 million is spent each year in the United States on liver transplantation for children and the ensuing hospitalizations (2). This sum of money covers 0.2% of total health care expenditures related to children, even though these children represent 0.0006% of the total pediatric population. Importantly, this disproportionate expenditure for liver transplantation in children could be cut in half if improved therapies for biliary atresia were developed that could abrogate or further delay the need for liver transplantation. Remarkably, little is known about the etiopathogenesis of biliary atresia; consequently, there has been slow progress in developing improved therapies or preventative strategies during the past decade. The purpose of this review is to summarize recent advances in the diagnosis and management of biliary atresia, examine the clinical outcome, describe the evolving theories of the etiology and pathogenesis of this disorder, and highlight gaps in our current knowledge.
Lippincott Williams & Wilkins